AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25747273
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with activated CIK cells (injection of 6.4 × 10(9) autologous CIK cells, 16 times during 60 weeks)
Trial: 25747273
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with activated CIK cells
Trial: 21114826
Drug: Specialist depression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialist depression disorder team (psychiatrist and psychotherapist jointly assessing and providing algorithm based drug and psychological treatment)
Trial: 21114826
Drug: Usual secondary
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual secondary care treatment
Trial: 29907887
Drug: YH4808 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (300 mg) after a single dose at fed state with a standard meal
Trial: 29907887
Drug: YH4808 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (300 mg) after a single dose at fed state with a high-fat meal
Trial: 29907887
Drug: YH4808 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (100 mg) after multiple dosing for 7 days in fed state with a standard meal
Trial: 24435507
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (10, 5, 5 mg/kg every 24 h)
Trial: 24435507
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (0.20‐0.25 mg/kg every 24 h)
Trial: 24435507
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (early postnatal age <8 days)
Trial: 24435507
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (early postnatal age <8 days)
Trial: 24435507
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (neonates >28 weeks)
Trial: 24435507
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (neonates >28 weeks)
Trial: 24435507
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (birth weight >1,000 g)
Trial: 24435507
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (birth weight >1,000 g)
Trial: 7439477
Drug: SADBE (squaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SADBE (squaric acid dibutylester) applied weekly to one side of the head
Trial: 29960684
Drug: High-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiotherapy (RT) at 60 Gy
Trial: 17937690
Drug: B221 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B221 (2 g every 5 hours for 3 days)
Trial: 945686
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository control group
Trial: 25941220
Drug: Cefazolin 2
RxNorm normalized name: cefazolin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 2 g
Trial: 25941220
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g
Trial: 26080912
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (270 mgI/ml of contrast medium, 80 kVp tube voltage scanning and 50% ASiR)
Trial: 26080912
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (350 mgI/ml of contrast medium, 120 kVp routine tube voltage)
Trial: 23271695
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bioactive food ingredients (epigallocatechin gallate, capsaicins, piperine, L-carnitine)
Trial: 19840309
Drug: Twice-daily pimecrolimus
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily pimecrolimus cream 1%
Trial: 19840309
Drug: Once-daily pimecrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily pimecrolimus cream 1%
Trial: 15286858
Drug: Creatine supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplement (20 g of Creatine monohydrate for 14 days)
Trial: 10394855
Drug: Daily doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily doses of 100 mg for 3 months (fingernail) or 4 months (toenail) - Group A
Trial: 10394855
Drug: Intermittent pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pulse therapy with daily doses of 400 mg - Group B
Trial: 10394855
Drug: Intermittent pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pulse therapy with daily doses of 300 mg - Group C
Trial: 10394855
Drug: Intermittent pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pulse therapy with daily doses of 200 mg - Group D
Trial: 10394855
Drug: Further treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further treatment with daily doses of 400 mg for non-cured patients
Trial: 7117360
Drug: Prednisone (PN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (PN 30 + 30 mg)
Trial: 7117360
Drug: Deflazacort (DF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort (DF 36 + 36 mg)
Trial: 30232528
Drug: GHB 50
RxNorm normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB 50 mg/kg orally
Trial: 24601887
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of plain 1% 2-chloroprocaine (Group C, n = 66)
Trial: 24601887
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of plain 0.5% bupivacaine (Group B, n = 64)
Trial: 20015098
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (4.0 mg)
Trial: 19537284
Drug: C/BPO HE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/BPO HE (clindamycin 1%-BPO 5% topical gel with hydrating excipients)
Trial: 19537284
Drug: C/BPO (clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/BPO (clindamycin 1%-BPO 5% topical gel without hydrating excipients)
Trial: 9882080
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen trometamol 25 mg (37 mg of the trometamol salt)
Trial: 9882080
Drug: Dexketoprofen free
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen free acid 25 mg
Trial: 9882080
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen trometamol 25 mg (repeated dose, twice daily for 7 days)
Trial: 2911205
Drug: Daunorubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin (50 mg/m2, IV) on days 1‐3; cytarabine (Ara‐C) (25 mg/m2, IV) bolus, followed by 160 mg/m2 as a continuous IV infusion daily for 5 days and 6‐thioguanine (6‐TG) (100 mg/m2 po) every 12 hr daily for 5 days (DAT)
Trial: 2911205
Drug: Amsacrine (190
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amsacrine (190 mg/m2, IV) on days 1‐3 with Ara‐C and 6‐TG at the above doses (AAT)
Trial: 2911205
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (alternating cycles of vincristine/methotrexate, cyclophosphamide/6‐TG, daunorubicin/hydroxyurea and Ara‐C/6‐TG)
Trial: 9348577
Drug: Cisplatin/5-FU (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/5-FU (group 1): Cisplatin 100 mg/m2 on day 1 followed by continuous infusion of 5-FU 1,000 mg/m2/day on days 2-6, repeated every 21 days for four cycles.
Trial: 9348577
Drug: Cisplatin/UFT (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/UFT (group 2): Cisplatin 100 mg/m2 on day 1 followed by oral UFT 300 mg/m2/day on days 2-20, repeated every 21 days for four cycles.
Trial: 8396102
Drug: Azithromycin 10
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 10 mg/kg (maximum 500 mg) for three days
Trial: 8396102
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V at a dose of 125 mg or 250 mg qid for ten days
Trial: 3701861
Drug: Classical conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical conditioning therapy (54 10‐min immersions of both hands in water at 43 degrees C, with whole‐body exposure to cold air at 0 degrees C, three times per day, 3 days per week, for 6 weeks)
Trial: 3701861
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (eight sessions of electromyograph feedback while listening to relaxation tapes, followed by 10 sessions of digital thermal feedback while listening to relaxation tapes)
Trial: 29066464
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (162 mg weekly)
Trial: 27602924
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation (50 Gy per 25 fractions) and 5‐fluorouracil infusion (arm A)
Trial: 27602924
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation (50 Gy per 25 fractions) and 5‐fluorouracil infusion combined with oxaliplatin (arm B)
Trial: 27602924
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with 5‐fluorouracil and oxaliplatin without radiation (arm C)
Trial: 20811556
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate (higher than 300 mg/d)
Trial: 20811556
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate (300 mg/d)
Trial: 20811556
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate (duration of therapy)
Trial: 20811556
Drug: Successful therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful therapy
Trial: 20811556
Drug: Symptom improvement
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom improvement with therapy
Trial: 18171211
Drug: Long-term daily
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term daily aspirin use
Trial: 16155280
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (E+P) therapy, n = 437
Trial: 10539778
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: iron + folate (60 mg and 250 microg, respectively) daily for 3 mo, then folate (250 microg) weekly for 4 mo
Trial: 10539778
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: folate daily, and 60 mg iron only once weekly for 3 mo, then weekly iron + folate for 4 mo
Trial: 10539778
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: folate daily for 3 mo and then weekly for 4 mo
Trial: 10539778
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation over 7 mo (30 doses)
Trial: 8690193
Drug: Oral lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral lactulose (20 g)
Trial: 8690193
Drug: Intracolonic lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracolonic lactose (20 g)
Trial: 8690193
Drug: Intracolonic SCFAs
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRACORONAL, DENTAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracolonic SCFAs (54 mmol/180 mL and 90 mmol/180 mL)
Trial: 7049781
Drug: Neutral soluble
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral soluble human (semi-synthetic) insulin
Trial: 26946343
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) every 8 weeks for 200 weeks
Trial: 24513806
Drug: Indomethacin plus
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin plus sublingual nitrate (group A)
Trial: 24513806
Drug: Indomethacin plus
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin plus sublingual placebo (group B)
Trial: 18440400
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of social support and secure attachment
Trial: 16158207
Drug: Detralex 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detralex 500 mg (2 tablets 3 times daily for 5 days after the operation)
Trial: 16158207
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Detralex treatment)
Trial: 12568734
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg OD of natural conjugated estrogens during 4 months
Trial: 1454434
Drug: APDT (Acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APDT (Acellular Pertussis Vaccine with Lederle Diphtheria and Tetanus Toxoids)
Trial: 1454434
Drug: APDT-T/J (Commercially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APDT-T/J (Commercially available Japanese Takeda vaccine)
Trial: 3931661
Drug: Meptazinol 1
RxNorm normalized name: meptazinol 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 1 mg kg‐1
Trial: 3931661
Drug: Pethidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.5 mg kg‐1
Trial: 30737551
Drug: S-1 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 adjuvant monotherapy
Trial: 15818609
Drug: Mental Health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental Health Treatment Court (MHTC)
Trial: 9291724
Drug: Cognitive‐Behavioral Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Therapy for Sexually Abused Preschoolers (CBT‐SAP)
Trial: 8241988
Drug: i.v. immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. immunoglobulin (1.0 g/kg once weekly for 120 days after transplant) plus CMV‐seronegative blood products
Trial: 14668456
Drug: Four-drug regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz
Trial: 14668456
Drug: Four-drug regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz
Trial: 14668456
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen containing zidovudine, lamivudine, and efavirenz
Trial: 9024266
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human insulin-like growth factor I (rhIGF-I) at 120 micrograms/kg BW twice daily (n = 15)
Trial: 9024266
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human insulin-like growth factor I (rhIGF-I) at 80 micrograms/kg BW twice daily (n = 7)
Trial: 9024266
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment in idiopathic growth hormone deficiency (GHD) (n = 11)
Trial: 3095080
Drug: 10 percent
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 percent mannitol solution
Trial: 20356687
Drug: Early salvage
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early salvage hormonal therapy (HT) initiated with PSA < 10 ng/mL
Trial: 20356687
Drug: Late salvage
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late salvage hormonal therapy (HT) initiated with PSA ≥ 10 ng/mL
Trial: 17942524
Drug: Interferon-beta (IFN-beta)
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta (IFN-beta) treatment
Trial: 19742086
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine and 5% prilocaine cream (Emla Astra)
Trial: 19742086
Drug: 50% diluted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% diluted Citanest solution with ring-type infiltration
Trial: 15804789
Drug: Swimming (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swimming (water therapy)
Trial: 8188164
Drug: Optimal conditions
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal conditions for serum specimen preparation (immediate centrifugation after clot formation)
Trial: 12629094
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 4 IU/m².d (approximately 0.045 mg/kg/d)
Trial: 12629094
Drug: After starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After starting estrogen treatment
Trial: 27543470
Drug: Early direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early direct current cardioversion (DCCV) and oral Amiodarone for 6 weeks (Group 2)
Trial: 22868212
Drug: 0.2 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg/kg NMC
Trial: 22868212
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg NMC
Trial: 22868212
Drug: 12.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 μg/kg NMC
Trial: 22868212
Drug: 50.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50.0 μg/kg NMC
Trial: 22868212
Drug: 2.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 μg/kg GRP
Trial: 22868212
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg NMC + 20.0 μg/kg [d‐Lys(3)]‐GHRP‐6
Trial: 22868212
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg NMC + 20.0 μg/kg N‐GRP‐EE
Trial: 22868212
Drug: 20.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.0 μg/kg N‐GRP‐EE
Trial: 22868212
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg NMB
Trial: 22868212
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg NMC in pre-weaned calves
Trial: 22868212
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg NMC in rats
Trial: 21126666
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of warm fluids at 37° C
Trial: 21126666
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of room temperature fluids
Trial: 19079957
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval
Trial: 15690266
Drug: Spinal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal 2-chloroprocaine 10 mg
Trial: 15690266
Drug: Spinal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal 2-chloroprocaine 20 mg
Trial: 15690266
Drug: Spinal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal 2-chloroprocaine 30 mg
Trial: 15690266
Drug: Spinal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal 2-chloroprocaine 40 mg
Trial: 15690266
Drug: Spinal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal 2-chloroprocaine 60 mg
Trial: 15690266
Drug: Spinal 2-chloroprocaine
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal 2-chloroprocaine 10 mg to 60 mg